Health Care·Pharmaceuticals·$49.1B
Zoetis Inc. (ZTS) is a leading global animal health company that develops and manufactures veterinary medicines and vaccines....
Earnings Per Share (EPS)
EPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.
Revenue Growth
Revenue growth is essential for understanding the company's market performance and demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
8Q
EPS Beat Rate
100%
Avg EPS Surprise
+5.48%
Avg Stock Reaction
-2.80%
In Q4 2025, Zoetis reported an EPS of $1.48, beating estimates by 5.87%. However, the stock declined by 2.35% the following day, indicating market skepticism despite the earnings beat.
Management Promises & Guidance
Overall, expectations for Zoetis are cautious given recent stock reactions despite consistent earnings beats. Investors are keen to see if the company can maintain growth in a competitive landscape.
Bull Case
The optimistic view hinges on strong demand for animal health products and successful new product launches, which could lead to significant revenue growth.
Bear Case
Conversely, if the company faces supply chain issues or increased competition, it could struggle to maintain its current profitability and market share.
Earnings Per Share (EPS)
N/AEPS is a key indicator of profitability and will show how well the company is managing its costs and generating income.
Revenue Growth
N/ARevenue growth is essential for understanding the company's market performance and demand for its products.
The print will turn on these two things.
Q1
What is the expected EPS for Q1-2026?
A strong EPS figure could indicate continued profitability and growth potential, while a lower figure may raise concerns about future performance.
Q2
How is Zoetis addressing supply chain challenges?
Given the current global supply chain issues, management's commentary on this topic will be crucial for assessing operational stability and future growth.
Why consensus could be wrong
The Street may underestimate Zoetis' ability to innovate and capture market share in emerging markets, which could drive stronger-than-expected growth.
Supporting Evidence
The company's consistent EPS beats indicate strong underlying performance.
Recent trends in pet ownership and livestock health demand may not be fully reflected in current estimates.
Key Risk
If Zoetis demonstrates significant revenue growth in emerging markets, it could challenge current bearish sentiment.
Pre-commit to what would confirm each case.
The market is debating whether Zoetis can sustain its growth trajectory amidst increasing competition and potential supply chain disruptions.
Bull Confirmed If
An EPS of $1.55 or higher would confirm strong operational performance and growth.
Bear Confirmed If
An EPS below $1.40 would raise concerns about profitability and market competitiveness.
Implied Move
±N/A
There is no options market data available to gauge investor sentiment ahead of the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Zoetis beats expectations, history suggests a potential average one-day move of around -2.80%, confirming the company's strong market position.
In-Line / Cautious
If results are in line with expectations, the stock may experience muted reactions as investors await more clarity on future guidance.
Miss
A miss could lead to a decline similar to the average one-day move of -2.80%, reflecting market disappointment and concerns over growth.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PARAMOUNT SKYDANCE C Class B
May 4, 2026